Neutra Life Sciences Expands Clinical Research Capabilities Through New Joint Ventures

Neutra Life Sciences, a subsidiary of Neutra Corp (OTC: NTRR), is making significant strides in the clinical research industry by securing new joint venture partnerships. These partnerships, including Epic Foot & Ankle Centers (http://www.epicfootandankle.com), Aspire Hospital Cancer Centers (http://www.aspirehealthcorp.com), and Radiant Dermatology & Aesthetics Clinic (http://www.radiantdermtx.com), mark a strategic expansion into podiatry, radiation oncology, and dermatology. This move not only diversifies Neutra Life Sciences' service offerings but also positions the company to meet the growing demand for specialized clinical research services.

The expansion into these medical specialties allows Neutra Life Sciences to cater to a broader patient population, thereby enhancing its competitive edge in the clinical research sector. By broadening its therapeutic areas, the company is better equipped to support Contract Research Organizations (CROs) and sponsors in accelerating the development of innovative treatments. Sydney Jim, President and CEO of Neutra Corp, emphasized the importance of this growth, stating, 'Our growth reflects the increasing demand for high-quality, integrated clinical research solutions.'

In addition to its expansion efforts, Neutra Corp has decided to wind down its subsidiary, VIVIS Corporation, to focus more resources on its life sciences and clinical research initiatives. This strategic shift underscores the company's commitment to advancing healthcare innovation and delivering value in sectors with stable regulatory environments and long-term growth potential. Neutra Life Sciences continues to build a robust network of clinical research sites, aiming to improve health outcomes through cutting-edge collaboration and exceptional service to its partners.